InvestorsHub Logo
Followers 32
Posts 12644
Boards Moderated 0
Alias Born 08/29/2012

Re: namtae post# 373447

Friday, 09/09/2022 4:07:08 PM

Friday, September 09, 2022 4:07:08 PM

Post# of 401931
Nice...

- "On September 20, 2017, the Company filed an ANDA with the FDA for generic version of OxyContin® (extended release Oxycodone Hydrochloride). OxyContin® is approved for the management of pain severe enough to require daily, around-the clock, long-term opioid treatment and for which alternative treatment options are inadequate. Development of this product has been reinitiated with a target filing in Q1 2023."



----------------------------------------------------------------------------------------------------------------------------------

MAKE ELITE GREAT AGAIN!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News